Emirates Oncology Society Advances Cancer Care Through AI and Personalised Medicine
The 7th Annual Emirates Oncology Society Conference concluded with pivotal recommendations to enhance cancer treatment through artificial intelligence, immunotherapy and tailored molecular approaches.
The 7th Annual Emirates Oncology Society Conference drew to a close in Dubai on Sunday, bringing together distinguished oncology practitioners and researchers from across the United Arab Emirates and beyond. The two-day scientific gathering culminated in comprehensive recommendations designed to elevate cancer care standards through technological innovation and precision medicine.
The conference emphasised three transformative priorities: expanding artificial intelligence applications to forecast treatment outcomes, broadening immunotherapy deployment for advanced-stage malignancies, and accelerating personalised cancer medicine through genetic mutation identification and molecularly-targeted interventions. These recommendations reflect the evolving landscape of modern oncology and the profession’s commitment to individualised therapeutic approaches.
The scientific programme addressed a diverse spectrum of malignancies across specialised sessions. Lung cancer received particular attention on the final day, with expert discussions centring on personalised strategies for non-small cell lung cancer harbouring EGFR mutations, advances in small cell lung cancer management, and treatment optimisation for uncommon genetic alterations including ROS1, HER2 and NTRK mutations. Molecular testing was highlighted as integral to identifying optimal patient-specific therapies.
Gastrointestinal cancer sessions examined metastatic colorectal cancer, pancreatic malignancy, cholangiocarcinoma and locally advanced rectal cancer, whilst specialists reviewed emerging therapeutic strategies for oesophageal and gastric cancers. The liver cancer programme focused specifically on immunotherapy advances in hepatocellular carcinoma, evaluating long-term outcomes and future management directions.
Beyond pharmacological innovation, the conference recognised palliative care’s essential role within comprehensive cancer treatment. Participants stressed the importance of addressing physical, psychological and social dimensions of care for both adult and paediatric patients alongside their families.
Delegates concluded that advancing cancer care requires strengthening institutional collaboration through multidisciplinary teams, expanding molecular diagnostic capacity, and fostering knowledge exchange amongst specialised centres locally and internationally. The emphasis on continuing professional development reflects the rapid pace of oncological advancement and the necessity for clinicians to remain abreast of emerging evidence and technological capabilities.
The conference’s seventh iteration demonstrates the United Arab Emirates’ growing prominence as a centre for specialised scientific discourse in oncology, facilitating the translation of research innovations into clinical applications that enhance patient outcomes across the region.
Source: WAM